Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

*The trial information contained on this page was imported from ClinicalTrials.gov. Click here to view this trial on ClinicalTrials.gov.

Back to Search Print this study
Overview

Full Title:
A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Myeloma Stage or Condition:
Multiple Myeloma
Study Phase:
Phase 2
Description

Summary/Purpose:
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Detailed Description:
Anti-myeloma bridging treatment is allowed for disease control while bb2121 is being manufactured. Three sites in Japan will be activated in 2019 and will be open for enrollment to patients in Japan.
Treatments & Arms

Recruitment Information & Eligibility

Locations / Centres

Additional Information